Top Stocks
The Best Healthcare Stocks Right Now (Updated June 2026)
These seven healthcare stocks combine recurring demand, identifiable franchises, and varying mixes of scale, profitability, and growth heading into June 2026.
Jun 11, 202614 MIN
TickerSpark Feed
healthcare
Everything tagged "healthcare" across research, earnings, and macro.
69 articles
OpinionENSG
Ensign’s short-report selloff is testing whether execution still beats the narrative
The short-report hit on Ensign is serious, but the selloff is running into a business that just posted record occupancy, 21.7% adjusted EPS growth, and higher full-year guidance. We see this as a test of whether allegations can overpower a long-running execution story, and right now execution still has the better numbers.
Jun 9, 20264 MIN
Research ReportENSG
The Ensign Group (ENSG): Quality Growth at a Premium
Ensign is turning skilled nursing into a repeatable growth machine, with double-digit revenue and EPS growth, record occupancy, and a balance sheet that still supports acquisitions. The stock looks like a quality compounder, but valuation keeps the stance at Buy on pullbacks.
Jun 8, 202625 MIN
Research ReportCOO
The Cooper Companies (COO): Buy on Growth and Optionality
Cooper Companies posted strong Q2 growth, with earnings and free cash flow improving despite a litigation charge. CooperVision remains the steady core, while CooperSurgical adds strategic upside after major recall claims were largely resolved.
Jun 5, 202625 MIN
Research ReportNVO
Novo Nordisk (NVO): Obesity Growth vs. 2026 Pricing Pressure
Novo Nordisk remains a premier cardiometabolic franchise, but near-term pricing pressure and a weak 2026 outlook are tempering the story. The stock looks attractive for patient investors who can look through the reset and wait for obesity and pipeline reacceleration.
Jun 4, 202623 MIN
OpinionMDT
Medtronic may have finally found its second act
Medtronic finally has a growth story that looks big enough to matter at the company level, not just in a niche product line. With cardiac ablation surging and valuation still well below faster-loved device peers, MDT looks like the more compelling catch-up trade here.
Jun 4, 20264 MIN
Research ReportONC
BeiGene (ONC): BRUKINSA Drives a Profitability Inflection
BeiGene has crossed from cash-burning biotech into a profitable global oncology platform, powered by BRUKINSA’s rapid growth and a strengthening balance sheet. The pipeline still matters, but the investment case now rests on commercial execution and self-funding momentum.
Jun 3, 202624 MIN
Research ReportMDT
Medtronic (MDT): Broad-Based Growth Is Finally Accelerating
Medtronic is showing its strongest top-line growth in a decade, led by cardiovascular and pulsed field ablation momentum. The stock looks like a balanced Buy for moderate-risk investors, though margin pressure and debt keep the turnaround case from being pristine.
Jun 3, 202626 MIN
Opinion
The GLP-1 trade is becoming a market-share war, not a rising-tide story
Investors still talk about obesity drugs like a category ETF, but the evidence now points to a leadership trade. Eli Lilly is widening the gap with stronger execution, better prescription momentum, and a more threatening pipeline just as Novo Nordisk faces pricing pressure and a weaker growth profile.
Jun 3, 20265 MIN
OpinionABVX
Abivax’s crash may be the market overpricing a safety scare after a real Phase 3 win
Abivax just posted the kind of Phase 3 efficacy biotech investors wait years to see, and the stock still got cut nearly in half because the market fixated on a safety overhang. That risk is real, but a 44.1% one-day collapse looks more like panic repricing than a fair read on a drug that delivered 50%+ remission in maintenance.
Jun 3, 20264 MIN
Research ReportABVX
Abivax (ABVX): Phase 3 UC Data Drives Upside
Abivax’s lead asset obefazimod delivered strong Phase 3 maintenance data in ulcerative colitis, shifting the story toward regulatory execution. The balance sheet is solid enough to fund the next catalysts, but the stock remains highly dependent on one program.
Jun 3, 202622 MIN
OpinionBSX
Boston Scientific’s selloff is what a real medtech reset looks like
Boston Scientific’s plunge looks like a real reset, not a bargain-bin overreaction. Management already cut 2026 growth guidance, then reinforced that Watchman weakness is tied to a worsening procedure mix that the market can’t just wave away.
May 28, 20264 MIN
On-Demand Research
Need research on a stock not covered here?
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator